HIV drug resistance: Dolutegravir is a second-generation HIV integrase inhibitor


Kravchenko A.V., Kanestri V.G.

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare, Moscow
The paper gives the results of two large international studies SALING and VIKING-3, on the basis of which dolutegravir (DTG) is recommended as part of second- and subsequent-line antiretroviral therapy (ART) regimens in case of ineffective previous treatment regimens incorporating not only protease or nonnucleoside reverse transcriptase inhibitors, but also first-generation HIV integrase inhibitor (II) [raltegravir (RAL) and elvitegravir (EVG)]. The SALING study has indicated that DTG used in combination with other antiretroviral drugs has a higher virologic efficacy and a higher genetic threshold to the development of resistance than RAL and is also well tolerated by previously treated patients. DTG used as part of an ART regimen using a higher daily dose (50 mg twice daily) (the VIKING-3 study) was effective and safe in patients having rich experience of therapy and HIV resistance to first-generation II (RAL and EVG) and viral multiple resistance to other classes of antiretroviral drugs.

Literature


1. Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe (Version 8.0; October, 2015). European AIDS Clinical Society. http://www.eacsociety.org.


2. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). April 8, 2015. http:// www.AIDSinfo.nih.gov.


3. Pokrovsky V.V., Yurin O.G., Kravchenko A.V., Belyaeva V.V., Kanestri V.G., Afonina L.Y., Ermak T.N., Buravtsova E.V., Shakhgildyan V.I., Kozyrina N.V., Narsia R.S., Zimina V.N., Pokrovskaya A.V., Efremova O.S. [Russian guidelines for the follow-up and treatment of HIV-infected patients]. Epidemiologiya i Infektsionnyie Bolezni. Aktualnyie Voprosyi 2014; 6(prilozhenie). 48 р. (In Russ).


4. Raffi F., Jaeger H., Quiros-Roldan E., Albrecht H., Belonosova E., Gatell J.M., Baril J.-G., Domingo P., Brennan C., Almond S., Min S., on behalf of the extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect. Dis. 2013; 13: 927–935. doi:10.1016/S1473-3099(13)70257-3.


5. Walmsley S., Baumgarten A., Berenguer J., Felizarta F., Florence E., Khuong-Josses M.-A., Kilby J.M., Lutz T., Podzamczer D., Portilla J., Roth N., Wong D., Granier C., Wynne B., Pappa K. Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy–Naive Patients: Week 96 and Week 144 Results from the SINGLE Randomized Clinical Trial. J. Acquir. Immune Defic. Syndr. 2015 Dec 15;70(5):515-9. doi:10.1097/QAI.0000000000000790.


6. Molina J.-M., Clotet B., van Lunzen J., Lazzarin A., Cavassini M., Henry K., Kulagin V., Givens N., de Oliveira C.F., Brennan C., on behalf of the FLAMINGO study team. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV 2015; 2: e127–е136. 2015 doi:10.1016/S2352-3018(15)00027-2.


7. Cahn P., Pozniak A.L., Mingrone H., Shuldyakov A., Brites C., Andrade-Villanueva J.F., Richmond G., Buendia C.B., Fourie J., Ramgopal M., Hagins D., Felizarta F., Madruga J., Reuter T., Newman T., Small C.B., Lombaard J., Grinsztejn B., Dorey D., Underwood M., Griffith S., Min S. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study Lancet 2013; 382: 700–708. http://dx.doi.org/10.1016/S0140-6736(13)61221-0.


8. Castagna A., Maggiolo F., Penco G., Wright D., Mills A., Grossberg R., Molina J.-M., Chas J., Durant J., Moreno S., Doroana M., Ait-Khaled M., Huang J., Min S., Song I., Vavro C., Nichols G., and Yeo J.M., for the VIKING-3 Study Group. Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study. J. Infect. Dis. 2014; 210: 354–362. doi: 10.1093/infdis/jiu051.


9. Vavro C.L., Huang J., Avatapally C., Min S., Ait-Khaled M. Durable efficacy and limited integrase resistance evolution in subjects receiving dolutegravir after failing prior integrase inhibititor (INI) regimens: week 48 results from VIKING-3 (abstract O_10). Rev. Antiviral Ther. Infect. Dis. 2014; 2: 13(abstract O_10).


About the Autors


For correspondence:
Prof. Kravchenko Aleksey Viktorovich, MD; Leading Researcher, Specialized Research Department of AIDS Epidemiology and Prevention, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare
Address: 15, Eighth Sokolinaya Gora St., Build. 2, Moscow 105275
Telephone: +7(495) 366-05-18
E-mail: kravtchenko@hivrussia.net


Similar Articles


Бионика Медиа